- Home
- SRCE vs PHAT Comparison
SRCE vs PHAT Comparison
Compare SRCE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRCE
- PHAT
- Stock Information
- Founded
- SRCE 1863
- PHAT 2018
- Country
- SRCE United States
- PHAT United States
- Employees
- SRCE N/A
- PHAT N/A
- Industry
- SRCE Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- SRCE Finance
- PHAT Health Care
- Exchange
- SRCE Nasdaq
- PHAT Nasdaq
- Market Cap
- SRCE 1.5B
- PHAT 1.2B
- IPO Year
- SRCE N/A
- PHAT 2019
- Fundamental
- Price
- SRCE $64.92
- PHAT $8.78
- Analyst Decision
- SRCE Hold
- PHAT Strong Buy
- Analyst Count
- SRCE 2
- PHAT 4
- Target Price
- SRCE $64.75
- PHAT $22.50
- AVG Volume (30 Days)
- SRCE 78.8K
- PHAT 1.9M
- Earning Date
- SRCE 10-24-2024
- PHAT 11-07-2024
- Dividend Yield
- SRCE 2.22%
- PHAT N/A
- EPS Growth
- SRCE 2.45
- PHAT N/A
- EPS
- SRCE 5.25
- PHAT N/A
- Revenue
- SRCE $369,012,000.00
- PHAT $26,270,000.00
- Revenue This Year
- SRCE N/A
- PHAT $6,714.96
- Revenue Next Year
- SRCE $1.11
- PHAT $293.69
- P/E Ratio
- SRCE $12.38
- PHAT N/A
- Revenue Growth
- SRCE 1.57
- PHAT N/A
- 52 Week Low
- SRCE $47.24
- PHAT $6.07
- 52 Week High
- SRCE $67.74
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- SRCE 58.11
- PHAT 23.73
- Support Level
- SRCE $57.92
- PHAT $8.91
- Resistance Level
- SRCE $67.74
- PHAT $19.05
- Average True Range (ATR)
- SRCE 1.73
- PHAT 1.74
- MACD
- SRCE 0.38
- PHAT -1.05
- Stochastic Oscillator
- SRCE 71.28
- PHAT 2.19
About SRCE 1st Source Corporation
1st Source Corp along with its subsidiary offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans which are given to privately owned business clients mainly located within regional market area, Consumer Services that consists of full range of consumer banking products and services, Trust and Wealth Advisory Services and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.